EVA1B

Summary

EVA1B (eva-1 homolog B, HGNC:25558) is a protein-coding gene on chromosome 1p34.3, encoding Protein eva-1 homolog B (Q9NVM1).

Predicted to be located in membrane.

Source: NCBI Gene 55194 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 23 total
• MANE Select transcript: NM_001304762

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25558
Approved symbol	EVA1B
Name	eva-1 homolog B
Location	1p34.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10647
Ensembl gene	ENSG00000142694
Ensembl biotype	protein_coding
Entrez	55194

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000270824, ENST00000490466, ENST00000902078, ENST00000937787

RefSeq mRNA: 2 — MANE Select: NM_001304762 NM_001304762, NM_018166

CCDS: CCDS406

Canonical transcript exons

ENST00000490466 — 3 exons

Exon	Start	End
ENSE00001824724	36323459	36323645
ENSE00001958171	36322030	36322725
ENSE00003916720	36322971	36323067

Expression profiles

Bgee: expression breadth ubiquitous, 214 present calls, max score 95.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.9158 / max 454.7009, expressed in 1724 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
11713	30.2803	1722
11714	0.6355	422

Top tissues by expression

267 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
descending thoracic aorta	UBERON:0002345	95.20	gold quality
stromal cell of endometrium	CL:0002255	95.08	gold quality
thoracic aorta	UBERON:0001515	94.87	gold quality
ascending aorta	UBERON:0001496	94.86	gold quality
metanephros cortex	UBERON:0010533	93.69	gold quality
endocervix	UBERON:0000458	93.57	gold quality
left coronary artery	UBERON:0001626	92.87	gold quality
aorta	UBERON:0000947	92.34	gold quality
ectocervix	UBERON:0012249	92.24	gold quality
right coronary artery	UBERON:0001625	92.21	gold quality
coronary artery	UBERON:0001621	91.85	gold quality
apex of heart	UBERON:0002098	91.44	gold quality
right ovary	UBERON:0002118	91.42	gold quality
body of uterus	UBERON:0009853	90.93	gold quality
popliteal artery	UBERON:0002250	90.65	gold quality
tibial artery	UBERON:0007610	90.64	gold quality
decidua	UBERON:0002450	90.33	gold quality
left uterine tube	UBERON:0001303	90.21	gold quality
omental fat pad	UBERON:0010414	90.00	gold quality
peritoneum	UBERON:0002358	89.94	gold quality
right lung	UBERON:0002167	89.85	gold quality
left ovary	UBERON:0002119	89.70	gold quality
spleen	UBERON:0002106	89.53	gold quality
mucosa of stomach	UBERON:0001199	89.33	gold quality
adipose tissue of abdominal region	UBERON:0007808	88.96	gold quality
placenta	UBERON:0001987	88.95	gold quality
minor salivary gland	UBERON:0001830	88.48	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	88.47	gold quality
cartilage tissue	UBERON:0002418	88.32	gold quality
lower esophagus muscularis layer	UBERON:0035833	88.15	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	113.29
E-MTAB-8271	yes	15.05
E-ANND-3	yes	5.24
E-CURD-112	yes	4.42
E-MTAB-7606	no	274.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting EVA1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-128-1-5P	99.33	60.46	332
HSA-MIR-5587-5P	99.07	68.58	838
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-5047	98.64	68.62	1035
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-6726-5P	95.97	63.72	841
HSA-MIR-920	95.97	63.95	811
HSA-MIR-4300	95.85	64.56	1003
HSA-MIR-5591-5P	95.85	64.76	1002

Literature-anchored findings (GeneRIF, showing 1)

• EVA1B to Evaluate the Tumor Immune Microenvironment and Clinical Prognosis in Glioma. (PMID:33889156)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	eva1bb	ENSDARG00000100698
mus_musculus	Eva1b	ENSMUSG00000050212

Paralogs (1): EVA1A (ENSG00000115363)

Protein

Protein identifiers

Protein eva-1 homolog B — Q9NVM1 (reviewed: Q9NVM1)

Alternative names: Protein FAM176B

All UniProt accessions (1): Q9NVM1

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the EVA1 family.

RefSeq proteins (2): NP_001291691, NP_060636 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR039500	EVA1_dom	Domain
IPR052461	EVA1_A/B	Family

Pfam: PF14851

UniProt features (8 total): modified residue 3, region of interest 2, chain 1, transmembrane region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NVM1-F1	62.51	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 85, 148, 158

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 111 (showing top): E2F_Q4_01, BOYLAN_MULTIPLE_MYELOMA_D_DN, TGCTGAY_UNKNOWN, chr1p34, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, PTF1BETA_Q6, RGAGGAARY_PU1_Q6, E2F_Q6_01, E2F_Q3_01, GAUSSMANN_MLL_AF4_FUSION_TARGETS_D_UP, MZF1_02, HMGIY_Q6, MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, ER_Q6_01

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

366 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EVA1B	SLFN13	Q68D06	768
EVA1B	MNMIP1	A4FU49	477
EVA1B	MTG2	Q9H4K7	475
EVA1B	C11orf68	Q9H3H3	446
EVA1B	CMPK2	Q5EBM0	443
EVA1B	DECR2	Q9NUI1	428
EVA1B	TMEM252	Q8N6L7	410
EVA1B	ETNK2	Q9NVF9	406
EVA1B	XPNPEP3	Q9NQH7	404
EVA1B	OASL	Q15646	398
EVA1B	RSAD2	Q8WXG1	387
EVA1B	IFIT3	O14879	386
EVA1B	OAS1	P00973	383
EVA1B	ZCCHC17	Q9NP64	382
EVA1B	GGTLC2	Q14390	378

IntAct

36 interactions, top by confidence:

A	B	Type	Score
EVA1B	SGTA	psi-mi:“MI:0915”(physical association)	0.720
SGTA	EVA1B	psi-mi:“MI:0915”(physical association)	0.720
EVA1B	CYSRT1	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	EVA1B	psi-mi:“MI:0915”(physical association)	0.560
HOXA1	EVA1B	psi-mi:“MI:0915”(physical association)	0.560
ANXA1	EVA1B	psi-mi:“MI:0915”(physical association)	0.560
CALR	EVA1B	psi-mi:“MI:0915”(physical association)	0.560
DLST	EVA1B	psi-mi:“MI:0915”(physical association)	0.560
EVA1B	NEK7	psi-mi:“MI:0915”(physical association)	0.560
DLK1	TCAF2	psi-mi:“MI:0914”(association)	0.530
CA14	EXOC5	psi-mi:“MI:0914”(association)	0.530
EVA1B	NRP1	psi-mi:“MI:0914”(association)	0.530
	ESYT2	psi-mi:“MI:0914”(association)	0.350
CA14	DNM1L	psi-mi:“MI:0914”(association)	0.350
EVA1B	C2CD2L	psi-mi:“MI:0914”(association)	0.350
EVA1B	TMEM131L	psi-mi:“MI:0914”(association)	0.350
CA14	ORC4	psi-mi:“MI:0914”(association)	0.350
PDPN	ORC4	psi-mi:“MI:0914”(association)	0.350

BioGRID (72): EVA1B (Two-hybrid), EVA1B (Affinity Capture-MS), EVA1B (Affinity Capture-MS), EVA1B (Co-fractionation), EVA1B (Two-hybrid), EVA1B (Two-hybrid), AREL1 (Affinity Capture-MS), PTPRK (Affinity Capture-MS), PPIL2 (Affinity Capture-MS), SDC2 (Affinity Capture-MS), SDC4 (Affinity Capture-MS), RNF166 (Affinity Capture-MS), LEMD3 (Affinity Capture-MS), TRIM27 (Affinity Capture-MS), WDR45B (Affinity Capture-MS)

ESM2 similar proteins: A0PJX4, A2A8U2, A4D2P6, A6QM06, D4A6L0, E1BBQ2, O15079, O60320, P12755, P49797, P97260, Q0D2I5, Q12770, Q15884, Q1RMB5, Q3TS39, Q3UPR0, Q4FZH1, Q5MNU5, Q5SNT2, Q5T848, Q5XKK7, Q60698, Q6A044, Q7T0Z7, Q7TMB0, Q7TPB0, Q810F0, Q86XR5, Q8BX43, Q8BXL9, Q8C419, Q8CA71, Q8K064, Q8K2Y3, Q8N114, Q8NDY8, Q8WV15, Q91WM6, Q92537

Diamond homologs: O88917, O88923, O94910, O95490, O97817, O97827, O97831, P58658, P58659, P86178, Q08CB3, Q68US5, Q80TR1, Q80TS3, Q8JZZ7, Q8K2Y3, Q91WM6, Q9H8M9, Q9HAR2, Q9NVM1, Q9SCV9, Q9XU98, Q9Z173, B3MFV7, B3N8M1, B4HS00, B4J780, B4KMZ1, B4P3A0, Q292N4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	21
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

437 predictions. Top by Δscore:

Variant	Effect	Δscore
1:36322722:TTGG:T	acceptor_gain	0.9900
1:36322723:TGG:T	acceptor_gain	0.9900
1:36322726:C:CC	acceptor_gain	0.9900
1:36322721:GTTGG:G	acceptor_gain	0.9800
1:36322724:GG:G	acceptor_gain	0.9800
1:36322725:GC:G	acceptor_loss	0.9800
1:36322726:C:T	acceptor_loss	0.9800
1:36322727:T:A	acceptor_loss	0.9800
1:36322953:T:TA	donor_gain	0.9700
1:36322970:CCG:C	donor_gain	0.9700
1:36323063:CCAGC:C	acceptor_gain	0.9700
1:36323064:CAGCC:C	acceptor_gain	0.9700
1:36323185:C:A	donor_gain	0.9700
1:36323456:CACCG:C	donor_loss	0.9600
1:36323457:A:AG	donor_loss	0.9600
1:36323891:A:AC	donor_gain	0.9600
1:36323892:C:CC	donor_gain	0.9600
1:36323892:CTCCG:C	donor_gain	0.9600
1:36322728:G:C	acceptor_loss	0.9500
1:36323184:T:TA	donor_gain	0.9500
1:36323190:A:C	donor_gain	0.9500
1:36322969:A:AC	donor_gain	0.9400
1:36322970:C:CC	donor_gain	0.9400
1:36323457:A:AC	donor_gain	0.9400
1:36323458:C:CC	donor_gain	0.9400
1:36324065:T:TA	donor_gain	0.9400
1:36323066:GCCTG:G	acceptor_loss	0.9300
1:36323067:CCT:C	acceptor_loss	0.9300
1:36323068:C:A	acceptor_loss	0.9300
1:36323069:T:G	acceptor_loss	0.9300

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000297447 (1:36322118 C>A,G,T), RS1000965000 (1:36322797 A>G), RS1001333537 (1:36323084 G>A,T), RS1002037077 (1:36322744 G>A,C,T), RS1003347480 (1:36325535 T>G), RS1003488537 (1:36325354 A>G,T), RS1003766771 (1:36325022 T>C), RS1004120633 (1:36324762 T>G), RS1004139716 (1:36324860 A>C), RS1004889841 (1:36324423 G>A), RS1005554377 (1:36325992 G>A,C), RS1005591187 (1:36322474 G>A,T), RS1005733060 (1:36323860 A>C,T), RS1005765675 (1:36323664 G>A), RS1005895174 (1:36323594 C>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90000025_914	Appendicular lean mass	2.000000e-23

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation	4
Tetrachlorodibenzodioxin	increases expression	3
Estradiol	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	increases expression	1
methyleugenol	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases methylation	1
ethyl-p-hydroxybenzoate	increases expression	1
hydroxyhydroquinone	increases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
eprenetapopt	affects expression, affects reaction	1
licochalcone B	increases expression	1
bisphenol S	decreases methylation, affects cotreatment	1
jinfukang	increases expression, affects cotreatment	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	increases expression	1
Atrazine	increases expression	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Calcitriol	increases expression, affects cotreatment	1
Cisplatin	affects cotreatment, increases expression	1
Dimethyl Sulfoxide	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.